专利号:US-10973847-B2 优先权日:2017-06-30 标题 :Core-to-surface polymerization for the synthesis of star polymers and uses thereof 发明人:JOHNSON JEREMIAH A; GOLDER MATTHEW R 权利人:MASSACHUSETTS INST TECHNOLOGY 摘要:Disclosed are methods, compositions, reagents, systems, and kits to prepare star polymers, as well as compositions and uses thereof. Various embodiments show that synthesis of these polymers contain low metal concentration to provide polymers for diverse biomedical applications including in vivo applications.
专利号:EP-2103609-A1 优先权日:2008-03-20 标 题:Catalyzed carbonylation in the synthesis of angiotensin ii antagonists 权利人:LEK PHARMACEUTICALS 摘要:One embodiment disclosed in the invention is the efficient synthesis of halogenated biaryl starting material via Grignard chemistry and the use thereof. Another embodiment of the invention is the reaction of catalyzed carbonylation of the 3'-(2'-halo-biphenyl-4-ylmethyl)-1,7'-dimethyl-2'-propyl-1H,3'H-[2,5']bibenzoimidazolyl (TLMH) using either gaseous carbon monoxide in a solvent mixture containing water; or formic acid salts optionally together with acetic acid in anhydrous solvent.
专利号:US-10005720-B2 优先权日:2013-04-05 标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same 发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L 权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL 摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.
专利号:US-8445693-B2 优先权日:2008-03-20 标 题 :Catalyzed carbonylation in the synthesis of angiotensin II antagonists 发明人:CASAR ZDENKO; COPAR ANTON; CLUZEAU JEROME; PREMRL ANDREJ 权利人:CASAR ZDENKO; COPAR ANTON; CLUZEAU JEROME; PREMRL ANDREJ; LEK PHARMACEUTICALS 摘要:One embodiment disclosed in the invention is the efficient synthesis of halogenated biaryl starting material via Grignard chemistry and the use thereof. Another embodiment of the invention is the reaction of catalyzed carbonylation of the 3′-(2′-halo-biphenyl-4-ylmethyl)-1,7′-dimethyl-2′-propyl-1H,3′H-[2,5′]bibenzoimidazolyl (TLMH) using either gaseous carbon monoxide in a solvent mixture containing water; or formic acid salts optionally together with acetic acid in anhydrous solvent.
专利号:US-8431712-B2 优先权日:2004-02-09 标 题 :Methods for the synthesis of pyridoxamine 发明人:KHALIFAH RAJA G; KEILITZ ROLAND; KOELLNER CHRISTOPH; DEGENHARDT THORSTEN; BRAND STEPHEN ROBERT 权利人:KHALIFAH RAJA G; KEILITZ ROLAND; KOELLNER CHRISTOPH; DEGENHARDT THORSTEN; BRAND STEPHEN ROBERT; NEPHROGENEX INC 摘要:The invention provides non-oxidative methods for the large scale manufacture of pyridoxamine (I) (4-aminomethyl-3-hydroxy-5-hydroxymethyl-2-methylpyridine): n nand salts thereof.n nThe invention also provides intermediate compounds for the synthesis of pyridoxamine, as well as compositions and methods for the treatment and/or prevention of conditions associated with the formation of post-Amadori advanced glycation end-products.
专利号:US-2008287407-A1 优先权日:2003-12-10 标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use 发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI 权利人:NITROMED INC 摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.
1: Imenshahidi M, Roohbakhsh A, Hosseinzadeh H. Effects of telmisartan on metabolic syndrome components: a comprehensive review. Biomed Pharmacother. 2024 Feb;171:116169. doi: 10.1016/j.biopha.2024.116169. Epub 2024 Jan 15. 2012–. Telmisartan. 2017 Jan 13. 56(6):1039-44; discussion 1045-6. doi: 10.2165/00003495-199856060-00007. 7:677-83. doi: 10.2147/VHRM.S9447. Epub 2011 Nov 15. 5: Podzolkov VI, Tarzimanova AI. Telmisartan v lechenii bol'nykh arterial'noĭ gipertonieĭ [Telmisartan in the treatment of hypertensive patients]. Ter Arkh. 2017;89(6):110-113. Russian. doi: 10.17116/terarkh2017896110-113.
合成参考文献
参考文献:10.4061/2011/132405 摘要:Tedla FM, Brar A, Browne R, Brown C. Hypertension in Chronic Kidney Disease: Navigating the Evidence. International Journal of Hypertension. 2011;2011():1–9. doi: 10.4061/2011/132405. 摘要:Ucciferri C, Falasca K, Mancino P, Pizzigallo E, Vecchiet J. Proteinuria in an African HIV-infected patient: effects of telmisartan. Infez Med. 2011 Jun;19(2):125–7. 参考文献:10.4061/2011/284823 摘要:Kinouchi K, Ichihara A, Bokuda K, Kurosawa H, Itoh H. Differential Effects in Cardiovascular Markers between High-Dose Angiotensin II Receptor Blocker Monotherapy and Combination Therapy of ARB with Calcium Channel Blocker in Hypertension (DEAR Trial). International Journal of Hypertension. 2011;2011():1–11. doi: 10.4061/2011/284823. 参考文献:10.1161/atvbaha.111.232058 摘要:Knorr M, Hausding M, Kröller-Schuhmacher S, Steven S, Oelze M, Heeren T, Scholz A, Gori T, Wenzel P, Schulz E, Daiber A, Münzel T. Nitroglycerin-induced endothelial dysfunction and tolerance involve adverse phosphorylation and S-Glutathionylation of endothelial nitric oxide synthase: beneficial effects of therapy with the AT1 receptor blocker telmisartan. Arterioscler Thromb Vasc Biol. 2011 Oct;31(10):2223–31. doi: 10.1161/atvbaha.111.232058. 参考文献:10.1097/maj.0b013e31821f0552 摘要:Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Yamada S, Ueda Y, Koide H. Changes in Urinary Albumin Excretion, Inflammatory and Oxidative Stress Markers in ADPKD Patients with Hypertension. The American Journal of the Medical Sciences. 2012 Jan;343(1):46–51. doi: 10.1097/maj.0b013e31821f0552.